Does TMS Therapy Work? What the Research Actually Shows

“Does it work” is the wrong first question for TMS, because the honest answer is a percentage, not a yes or no. Repetitive transcranial magnetic stimulation delivers precisely targeted magnetic pulses to the prefrontal cortex, a brain region reliably underactive in depression, to encourage that circuit back into a healthier pattern of activity. Antidepressant medication remains the appropriate first step for most people with depression, and it works for the majority of them. TMS exists for the substantial minority left over: people who have given medication a real trial and still aren’t well.

What This Page Covers

• What the FDA actually cleared TMS to treat, and for whom
• The real response and remission numbers, not marketing rounding
• How TMS compares to trying yet another medication
• Whether the benefit actually lasts after treatment ends
• How TMS stacks up against other treatment-resistant depression options
• Who is, and is not, a good candidate

What the FDA Actually Cleared, and When

TMS is not a wellness trend. The Neuronetics NeuroStar TMS Therapy System received its original FDA clearance in 2008 as a Class II device specifically for treating major depressive disorder in adults who have not received satisfactory improvement from prior antidepressant medication. That indication matters more than it might seem: TMS was cleared for a specific population, people who have already tried and not responded to medication, not as a general first-line depression treatment competing with antidepressants on equal footing.

The Clinical TMS Society’s consensus review, written by leading TMS researchers and clinicians and based on a systematic review of published clinical trials, concluded that daily left prefrontal TMS “has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant.” That is a deliberately narrow, evidence-graded statement, and it is the accurate one.

The Real Numbers Behind “It Works”

According to Harvard Medical School, approximately 50% to 60% of people with depression who have tried and not benefited from medication experience a clinically meaningful response with TMS, and about one-third of that group reaches full remission, meaning they no longer meet criteria for major depressive disorder. Those numbers describe a real, well-tolerated option for a population that has often already spent months cycling through medications, not a cure that works for everyone who tries it.

Side effects are also part of why those numbers hold up in practice. Per Harvard Medical School, TMS does not require anesthesia and is generally very well tolerated, with headache during or after treatment as the most common side effect. A rare but serious risk is seizure, which is why screening for seizure history and certain implants happens before treatment starts.

TMS vs. Trying Another Medication

For someone who has already tried one antidepressant without success, the realistic alternative to TMS is usually not “no treatment,” it’s trying another medication. Per Harvard Medical School, roughly two-thirds of people with depression don’t get adequate relief from the first antidepressant they try, and each subsequent medication trial tends to be less likely to help than the one before it, not more. That declining-returns pattern is precisely the clinical gap TMS was developed to address: a different mechanism, delivered directly to the brain circuits involved, for people whose odds with another prescription are already getting worse.

Does the Benefit Actually Last?

This is where a lot of marketing gets vague, and the actual research is more useful than the vagueness suggests. A multisite, naturalistic follow-up study tracked 257 patients with pharmacoresistant major depression for a full year after completing acute TMS treatment. Among the patients who had responded or remitted by the end of acute treatment, 62.5% continued to meet response criteria throughout the entire 12-month follow-up period. About 36.2% of patients received a brief course of TMS retreatment at some point during the year to maintain their improvement, averaging about 16 additional treatment days.

That is a realistic picture of durability: TMS is not a one-time fix that guarantees permanent remission, but for most people who respond, the improvement holds, and for those it doesn’t hold for, a brief booster course is a normal part of management rather than evidence the original treatment failed.

How TMS Compares to Other Treatment-Resistant Options

Nothing forces a choice between exactly one option. Here is how the major treatment-resistant depression paths compare on the dimensions that actually affect a decision.

Option	Invasiveness	Typical Course	What the Evidence Shows
Switching or augmenting medication	Non-invasive, oral	Ongoing, reassessed every 4 to 8 weeks	Each subsequent medication trial tends to help fewer people than the last
TMS	Non-invasive, no anesthesia	Daily sessions over 4 to 6 weeks	50% to 60% response, about a third remission, in treatment-resistant patients
Electroconvulsive therapy (ECT)	Requires anesthesia	Multiple sessions, typically 2 to 3 per week	The most potent option for severe, treatment-resistant depression, with a higher side effect burden including short-term memory effects

Who TMS Is, and Isn’t, For

TMS was cleared for adults with major depressive disorder who have not had satisfactory improvement from at least one prior antidepressant trial. On the other side of that same evidence base, the Clinical TMS Society consensus and the device’s original FDA safety review both point to specific exclusions: TMS is generally not used for people with certain metal implants or devices in or near the head, some cochlear implants, or a personal history of seizures, because the pulses could theoretically provoke a seizure in someone already predisposed to them. A prescriber reviews this history before recommending TMS, and TMS is delivered in specialized clinics, not something started without that evaluation.

How Siggy Approaches This

Siggy’s clinical scope today is medication management for anxiety and depression, reviewed and approved by a licensed prescriber. TMS is a separate, procedural treatment delivered in a specialized clinic, and Siggy does not perform or replace it. Where Siggy fits into this picture is upstream: making sure a medication trial has actually had a fair, adequately dosed chance to work, tracking side effects and response between visits instead of waiting for the next scheduled appointment, and recognizing early when a case genuinely isn’t responding, so a referral for a higher level of care like TMS happens sooner rather than after months of drift.

What Members Are Saying

DK

D.K., 41

Tried Two Antidepressants Before Considering TMS

“I’d been through two medications with no real change and was starting to think nothing would work. Having someone actually track what wasn’t working, instead of just refilling the same prescription, is what got me to ask about other options in the first place.”

SB

S.B., 37

Currently On Medication, Researching Next Steps

“I’m not at the TMS stage yet, but knowing my care team is paying attention to whether my current medication is actually working, not just assuming it is, makes the idea of ‘what’s next’ feel less scary.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

If you are having thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

TMS has real, FDA-backed evidence behind it for people who haven’t responded to medication, but getting there starts with knowing whether your current treatment has actually been given a fair chance. Start your anonymous intake with SiggyMD to get a medication plan reviewed by a licensed prescriber, with ongoing tracking so you know sooner rather than later if it’s time to talk about what’s next. If you want the fuller picture of how TMS works session to session, our guide to what TMS therapy is covers the mechanism and what to expect in more detail.

Ready for care that actually tracks whether your treatment is working? Get started with SiggyMD today.

Sources

1. U.S. Food and Drug Administration. 510(k) Premarket Notification: NeuroStar TMS Therapy System, K083538. FDA Center for Devices and Radiological Health. 2008.
2. Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimulation. 2016;9(3):336-346.
3. Dunner DL, Aaronson ST, Sackeim HA, et al. A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. Journal of Clinical Psychiatry. 2014;75(12):1394-1401.
4. Stern AP. Transcranial Magnetic Stimulation (TMS): Hope for Stubborn Depression. Harvard Health Blog, Harvard Medical School. Updated 2018.